ARCHIVES

ORI Final Findings Of Scientific Misconduct

This article is from The Cancer Letter archive.

Vol. 20 No. 35 | September 16, 1994

Download PDF Visit The Full Archive

Related Articles

Funding opportunities listed.

November 19, 2004

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

In Brief: National Patient Advocates Foundation Formed To Seek Health Insurance Reform

November 15, 1996

FDA Approves Manufacturer Of IVAX Paclitaxel Ingredient.

June 29, 2001

NIH offers student loan repayment program, deadline is Dec. 31.

November 21, 2003

NCI Approved CTEP Trials For the Month of August

August 31, 2012